Symposium Agenda



*Agenda subject to change

Reception, 5:30-7 p.m.

Whitaker Campus Commons

Welcome & Introductions, 7 p.m.

Hodson Auditorium, Rosenstock Hall

  • Debbie Ricker, Ph.D.
    Interim President, Hood College
  • Ethan Dmitrovsky, M.D.
    Director, Frederick National Laboratory for Cancer Research

Keynote, 7:30 p.m.

"Reaching the 2030 SDG Target for AIDS: Success, Challenges and Prospects"
Salim S. Abdool Karim, Ph.D.
Director, Centre for AIDS Program of Research, South Africa (CAPRISA)
CAPRISA Professor of Global Health, Columbia University
Special Advisor to the Director-General of the World Health Organization
Pro Vice-Chancellor (Research), University of KwaZulu-Natal
Adjunct Professor of Medicine, Weill Medical College of Cornell University

Free and open to the public; registration required.

Session 1: Epidemiology of HIV Disease

  • 7:30-8 a.m., Networking
    Continental breakfast will be provided.
  • 8-8:15 a.m., Introduction
    Douglas Lowy, Principal Deputy Director, National Cancer Institute
  • 8:15-9 a.m., HIV: History, Current Status, Future Challenges and Strategies
    Speaker TBD

Session 2: Vaccine Prevention

  • 9:05-9:30 a.m., Modeling and Computational Approaches to Next Generation Vaccine Design for T-Cell and Antibody Responses
    Arup K. Chakraborty,  John M. Deutch Institute Professor, Professor Chemical Engineering, Physics and Chemistry
    Massachusetts Institute of Technology
  • 9:35-10 a.m., T-Cell Vaccines Targeting Conserved, Constrained Epitopes
    Gaurav D. Gaiha,  Principal Investigator and Group Leader, Ragon Institute of MGH, MIT and Harvard
  • 10:05-10:15 a.m., Break
  • 10:15-10:40 a.m., Efficacy and Mechanisms of Unconventionally Restricted CMV-Vectored T-Cell Vaccines
    Louis J. Picker, Professor, VGTI-Vaccine and Gene Therapy Institute, Molecular Microbiology and Immunology Graduate Program, School of Medicine, Program in Molecular and Cellular Biosciences, School of Medicine, Oregon Health & Science University
  • 10:45-11:10 a.m., HIV Vaccine Immunogen Design for Induction of Broadly Neutralizing Antibodies
    William Schief, Professor, Department of Immunology and Microbiology, Scripps Research Institute
  •  11:15-11:40 a.m., Application of Systems Immunology to Improve Vaccines
    Bali Pulendran, Violetta L. Horton Professor, Stanford University School of Medicine
  • 11:45 a.m.-12:10 p.m., Improving Efficacy with Alternative Vaccine Delivery Approaches
    Darrell Irvine, Underwood-Prescott Professor, Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology
  • 12:15-1:30 p.m., Lunch

Session 3: Non-Vaccine Prevention: bNAbs and Long-Acting Anti-Retrovirals

  • 1:30-1:55 p.m., How do Antibodies Protect Against HIV
    Dennis Burton, Chair and Professor, Department of Immunology and Microbiology, Scripps Research Institute, Director, AIDS Vaccine Research IAVI Neutralizing Antibody Center
  • 2-2:25 p.m., Lifelong Delivery of Monoclonal Antibodies AAV Vectors
    Ronald Desrosiers, Professor and Vice Chair, Department of Pathology, University of Miami Miller School of Medicine
  • 2:30-2:55 p.m., Long-acting Injectable Cabotegravir for HIV Pre-exposure Prophylaxis: State of the Science, Implementation and Looking to the Future
    Raphael J. Landovitz, Professor of Medicine, Interim Chief, Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, Director, UCLA Center for Clinical AIDS Research & Education, Co-Director Center for HIV Identification, Prevention, and Treatment Services
  • 2:55-3:10 p.m., Break
  • 3:10-3:35 p.m., Preclinical Evaluations of Long-acting Lenacapavir PrEP in Nonhuman Primates Challenged with Simian-tropic HIV-1 
    Gregory Del Prete, Associate Director for Nonhuman Primate Resources, Principal Investigator, Viral Persistence Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research
  • 3:40-4:05 p.m., Advancements in Clinical Development of Lenacapavir
    Laurie VanderVeen, Director, HIV Clinical Virology, Gilead Sciences 
  • 6 p.m., Speaker/Panelist Dinner
    Location TBD (Hood College)

Session 4: Treatment of HIV Infection: State of the ART

  • 7:30-8 a.m., Networking
    Continental breakfast will be provided
  • 8:05-8:25 a.m., PEPFAR at 20
    Nelson L. Michael, Director, Center for Infectious Disease Research, Walter Reed Army Institute of Research
  • 8:30-8:55 a.m., Experience with Roll Out of Modern ART in an Upper Middle-Income Country
    Gustavo Reyes TerĂ¡n, Head of the Coordinating Commission, National Health Institutes and High Specialty Hospitals, Mexico
  • 9-9:25 a.m., Current Status and Challenges in Treatment of HIV Infection
    Steven Deeks, Professor of Medicine, University of California San Francisco, Faculty Member, Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital
  • 9:30-9:55 a.m., Chronic Inflammation and Other Co-Morbidities in Treated HIV Infection
    Peter W. Hunt, Professor of Medicine, University of California San Francisco Associate Chief for Research, ZSFG-UCSF Department of Medicine, Department of Medicine, Division of Experimental Medicine
  • 9:55-10:10 a.m., Break

Session 5: CNS Infection in HIV; KSHV

  • 10:10-10:35 a.m., CNS Infection with HIV
    Sarah Joseph, Assistant Professor, University of North Carolina School of Medicine, Microbiology and Immunology
  • 10:40-11:05 a.m., KSHV Virology and Epidemiology
    Elizabeth Yu Chiao, M.D., MPH, Professor, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
  • 11:10-11:35 a.m., Insights on the Pathogenesis and Treatment of KSHV-Associated Tumors and Other Diseases
    Robert Yarchoan, Chief, HIV and AIDS Malignancy Branch, Center for Cancer Research, Director, Office of HIV and AIDS Malignancy, National Cancer Institute 
  • 11:40 a.m.-12:05 p.m., KSHV PDX Models to Guide Treatment
    Laurie T. Krug, Stadtman Investigator, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute
  • 12:05-1:30 p.m., Lunch

Session 6: HIV Rebound Competent Viral Reservoir and Towards a Cure

  • 1:30-1:55 p.m., Molecular Aspects of the HIV Reservoir
    Xu Yu, Associate Professor of Medicine, Harvard Medical School, Physician Investigator, Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Associate Immunologist, Brigham and Woman's Hospital
  • 2-2:25 p.m., Towards an HIV Cure: Novel Approaches to Reduce and Control the HIV Reservoir
    Sharon Lewin, Director, The Peter Doherty Institute for Infection and Immunity, Professor of Medicine, The University of Melbourne
  • 2:30-2:55 p.m., Gene Therapy for HIV Infection
    Hans-Peter Kiem, Deputy Director, Translational Science and therapeutics Division, Professor, Vaccine and Infectious Disease Division
  • 3-3:15 p.m., Break
  • 3:15-4:15 p.m., Panel Discussion: Moderator - John Mellors, MD, Department of Medicine, University of Pittsburgh
    • Mike McCune, Head, HIV Frontiers, Bill & Melinda Gates Foundation
    • Mike Saag, Professor of Medicine-Infectious Diseases, University of Alabama at Birmingham
    • Daria Hazuda, Head of Infectious Diseases and Vaccine Research, Generate Biomedicines (former VP of Infectious Diseases and Vaccines and Chief Scientific Officer, Merck Cambridge Research)
    • Lynda Dee, Community Engagement Coordinator DARE MDC AIDS Action Baltimore, Executive Director
    • John Coffin, Tufts University School of Medicine
  • 4:15 p.m., Closing Remarks (meeting summary, vision for the future of HIV)
    • Jeff Lifson, Director, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research
    • Mary Carrington, Director, Basic Science Program, Frederick National Laboratory for Cancer Research